

WHAT IS CLAIMED IS:

1. A method of reducing the asthma exacerbation rate in an asthma patient with nasal polyposis, comprising administering to said asthma patient an effective amount of benralizumab or an antigen-binding fragment thereof, wherein the administration reduces the patient's exacerbation rate.
2. A method of treating asthma, comprising administering to an asthma patient with nasal polyposis an effective amount of benralizumab or an antigen-binding fragment thereof, wherein the patient has a blood eosinophil count of at least 300 cells/ μ l prior to the administration.
3. A method of treating asthma, comprising administering to an asthma patient with nasal polyposis an effective amount of benralizumab or an antigen-binding fragment thereof, wherein the patient has a forced expiratory volume (FEV₁) of less than 80% predicted value prior to the administration.
4. A method of treating asthma, comprising administering at least two doses of benralizumab or an antigen-binding fragment thereof to an asthma patient with nasal polyposis.
5. The method of any one of claims 2-4, wherein the administration reduces the patient's annual exacerbation rate.
6. The method of claim 5, wherein the administration improves the patient's Sino-Nasal Outcome Test-22 (SNOT-22) score.
7. The method of any one of claims 1 or 3-6, wherein the asthma is eosinophilic asthma.
8. The method of any one of claims 1 or 3-7, wherein the patient has a blood eosinophil count of at least 300 cells/ μ l.
9. The method of any one of claims 1, 2, or 4-8, wherein, the patient has a forced expiratory volume (FEV₁) of less than 75% predicted value prior to the administration.
10. The method of any one of claims 1-9, wherein the patient has an asthma control questionnaire 6 (ACQ-6) score of at least 1.5 prior to the administration.

11. The method of any one of claims 1-3 or 5-10, wherein at least two doses of benralizumab or an antigen-binding fragment thereof are administered to the patient.
12. The method of any one of claims 1 or 6-11, which reduces the annual exacerbations rate following administration of the antibody or antigen-binding fragment thereof.
13. The method of any one of claims 1 or 6-12, wherein the annual exacerbation rate is reduced by at least 40%.
14. The method of claim 13, wherein the annual exacerbation rate is reduced by at least 50%.
15. The method of claim 14, wherein the annual exacerbation rate is reduced by at least 60%.
16. The method of any one of claims 1-15, wherein the patient's SNOT-22 score is reduced by at least 7 points.
17. The method of any one of claims 1-16, wherein the patient's SNOT-22 score is reduced by at least 8 points.
18. The method of any one of claims 1-17, wherein the patient uses high-dose inhaled corticosteroids (ICS).
19. The method of any one of claims 1-18, wherein the patient uses long-acting β_2 agonists (LABA).
20. The method of any one of claims 1-19, wherein the patient uses oral corticosteroids (OCS).
21. The method of any one of claims 1-20, wherein the patient has a history of exacerbations.
22. The method of claim 21, wherein the history of exacerbations comprises at least two exacerbations in the year prior to the administration of the benralizumab or antigen-binding fragment thereof.
23. The method of claim 21 or 22, wherein the history of exacerbations comprises no more than six exacerbations in the year prior to the administration of the benralizumab or antigen-binding fragment thereof.

24. The method of any one of claims 1-23, wherein the benralizumab or antigen-binding fragment thereof is administered at about 30 mg per dose.
25. The method of any one of claims 1-24, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks to once every twelve weeks.
26. The method of claim 25, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks.
27. The method of claim 25, wherein the benralizumab or antigen-binding fragment thereof is administered once every eight weeks.
28. The method of claim 25, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.
29. The method of any one of claims 1 to 28, wherein the benralizumab or antigen-binding fragment thereof is administered parenterally.
30. The method of claim 29, wherein the benralizumab or antigen-binding fragment thereof is administered subcutaneously.
31. The method of any one of claims 1 to 30, wherein the benralizumab or antigen-binding fragment thereof is administered in addition to corticosteroid therapy.
32. A method of reducing the SNOT-22 score in an asthma patient with nasal polyposis, comprising administering to an asthma patient 30 mg of benralizumab or an antigen-binding fragment thereof, wherein the patient has an blood eosinophil count of at least 300 cells/ μ l prior to the administration.
33. The method of claim 32, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.
34. The method of claim 32, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks.
35. The method of claim 32, wherein the benralizumab or antigen-binding fragment thereof is administered once every eight weeks.

36. The method of any one of claims 32-35, wherein administration of the benralizumab or antigen-binding fragment decreases exacerbation rates of asthma.
37. The method of any one of claims 32-36, wherein administration of the benralizumab or antigen-binding fragment decreases annual exacerbation rates of asthma.
38. The method of any one of claims 32-36, wherein the administration is subcutaneous.
39. A method of treating asthma in patient with nasal polyposis, comprising administering the patient 30 mg of benralizumab or an antigen-binding fragment thereof, wherein the patient has an blood eosinophil count of at least 150 cells/ μ l prior to the administration.
40. The method of claim 39, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.
41. The method of claim 39, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks.
42. The method of claim 39, wherein the benralizumab or antigen-binding fragment thereof is administered once every eight weeks.
43. The method of any one of claims 39-42, wherein the administration is subcutaneous.
44. The method of any one of claims 1-43, wherein the patient's St. George's Respiratory Questionnaire (SGRQ) score is reduced.
45. The method of any one of claims 1-44, wherein the patient's SNOT-22, SGRQ, and ACQ-6 scores are reduced, and the patient's FEV is increased.
46. The method of any one of claims 1-45, wherein the patient's SNOT-22 score is reduced by at least 8.9.
47. The method of any one of claims 1-46, wherein the patient's SGRQ score is reduced by at least 4 units, the patient's ACQ score is reduced by at least 0.5, the patient's FEV is increased by at least 200 mL, and/or the administration prevents asthma exacerbations for at least 24 weeks from the first administration.

48. The method of claim 47, wherein the patient's SGRQ score is reduced by at least 4 units, the patient's ACQ score is reduced by at least 0.5, the patient's FEV is increased by at least 200 mL, and the administration prevents asthma exacerbations for at least 24 weeks from the first administration.